Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PR Newswire  | 
A-
A+
Lesemodus
playAudio
playTeilen
Die Bank of America ist eines der weltweit größten Finanzinstitute und bekannt für ihre umfassenden Dienstleistungen sowie die Übernahme von Merrill Lynch während der Finanzkrise 2008.
- ©iStock

PR Newswire

PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.

A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto/Berger Montague)

Shareholders of ADMA may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Caitlin Adorni at cadorni@bergermontague.com or (267) 764- 4865 or by visiting our website.

ADMA, headquartered in Ramsey, New Jersey, is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty biologics for the treatment of immune deficiencies and infectious diseases. Its flagship product, ASCENIV, is an intravenous immune globulin therapy indicated for the treatment of Primary Humoral Immunodeficiency (PI).

Werte aus dem Artikel:
ADMA Biologics Aktie 10,98 $ -0,77%

If you are an ADMA investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267) 764-4865.

About Berger Montague

Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

For more information or to discuss your rights, please contact:
Andrew Abramowitz
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com

Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigates-adma-biologics-incs-board-of-directors-for-breach-of-fiduciary-duty-nasdaq-adma-302864696.html

SOURCE Berger Montague



Dein Kommentar zum Artikel im Forum

Jetzt anmelden und diskutieren Registrieren Login

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Themen im Trend

Weitere Vorteile:

  • Kursalarme
  • Watchlists & Musterdepots
  • Börsenspiele & Community-Forum
  • Historische Kurse im CSV-Format
  • News & Themen abonnieren